Dry blending of Sanhuang Shuanghuang Tablets Veterinary Grade API for direct compression tablets begins with sieve classification and moisture correction. The incoming extract is normally a fine hygroscopic powder with batch-to-batch color and flow variation; therefore each lot is sampled according to ISO 2859-1 and tested for loss on drying at 105°C. A moisture specification of ≤5.0% w/w is applied before milling. Batches exceeding this are dried in a forced-air oven at 40–45°C for not more than 4 h or in a vacuum dryer at −0.08 MPa to −0.09 MPa. The dried extract is passed through a conical mill fitted with a 0.6 mm screen; oversize retention above 150 µm is limited to 10% w/w to prevent segregation in downstream direct compression feeds. Relative humidity in the compression suite is maintained below 60% RH; above this threshold the powder adsorbs moisture, bridges in the hopper, and produces sticky tablet surfaces.

In the dry blend, the extract fraction is normally set between 20% and 60% w/w depending on the filed dose. The remaining solids include microcrystalline cellulose, spray-dried lactose monohydrate, partially pregelatinised maize starch, and a low-moisture disintegrant. Colloidal silicon dioxide is first pre-blended with the extract at 0.5%–1.0% w/w to reduce hygroscopic bridging. Crospovidone or sodium starch glycolate is added at 2.0%–4.0% w/w. Magnesium stearate is withheld until the final 2–3 min of blending and is added at 0.25%–0.5% w/w. Adding lubricant too early reduces compact tensile strength and increases friability under USP <1216>. Lubrication is performed in a bin blender at 10–15 rpm after pre-blending; mixing above 5 min produces fines and reduces disintegration.

Tablet compression on a rotary press with a precompression station is preferred when the extract fraction exceeds 50% w/w. Precompression force is set to 6–8 kN for 8 mm flat-faced beveled tooling, followed by main compression at 12–18 kN to reach hardness of 50–80 N. Capping and lamination become significant above 90 N because the botanical extract has low plastic deformation capacity. Friability must remain ≤1.0% w/w per USP <1216>, and disintegration is tested at 37±2°C in water per USP <701> with a limit of not more than 30 min. If disintegration exceeds this, sodium starch glycolate is increased stepwise to 4.0% w/w while the lubricant fraction is held constant. Published data for this specific multi-herbal extract in direct compression are limited; development trials on a 12-station rotary press are required before final hardness limits are fixed.

For dose-release verification, USP <711> Apparatus 2 is operated at 50 rpm with 900 mL of purified water at 37±0.5°C. Because no harmonised public monograph exists for every marker of this multi-herbal extract, release specifications are tied to the registered veterinary reference product or to a validated in-house dissolution method. A qualified in-house method typically uses the 45 min time point as the primary control, with the target set during process qualification. The finished tablets are edge-polished and coated when required; film coating is preferred over sugar coating because the extract is moisture-sensitive and sugar coating increases water exposure. The terminal product is an oral veterinary tablet for cattle, swine, or companion animals produced under non-sterile GMP conditions.

What Limits Sterile-Filtration Throughput in Injectable Solutions?

Preparation of an injectable solution from the Sanhuang Shuanghuang Tablets Veterinary Grade API places the main constraint on particle load and membrane fouling rather than on dissolution rate. The extract is formulated in water for injection under nitrogen blanketing to limit oxidation of phenolic markers. The injection-grade powder is pre-dried to ≤3.0% w/w moisture and tested for bioburden, bacterial endotoxins, heavy metals, and residual solvent before use. The extract is added slowly to water for injection at 25–35°C under a bottom-mounted magnetic impeller. Where the lot is poorly dispersible, high-shear dispersion at 2,000–4,000 rpm may be applied for not more than 5 min; prolonged shear creates foam and accelerates surface denaturation of extracted proteins.

Clarification is performed by a staged filtration sequence. The bulk solution is first passed through a 0.45 µm polyethersulfone membrane, then through a 0.22 µm double-layer sterilizing-grade filter. Filter sizing is based on a Vmax study rather than a fixed cartridge area; colloidal polysaccharides and tannin-protein complexes in the botanical extract can reduce throughput to ≤80 L/m² at a differential pressure of 0.8 bar if the solution is not pre-clarified. A disc-stack centrifuge operating at 6,000–8,000 rpm is used before membrane filtration when clarified extract lots show persistent haze. The pH is buffered with 10 mM citrate or phosphate buffer; final pH is held between 5.5 and 6.5. Alkaloid precipitation may occur above 7.0, while pH values below 4.5 can increase hydrolysis of flavonoid glycosides.

Containers are filled under Grade A conditions with Grade B background per EU GMP Annex 1 and ISO 13408-1. If terminal sterilization at 121°C for 15 min is selected, forced degradation studies must demonstrate marker recovery above 95%. Because published data for this specific combination under terminal steam sterilization are limited, many facilities default to sterilizing filtration followed by aseptic filling, with filter integrity testing per ASTM F838-20 before and after use. Endotoxin testing per USP <85> must be validated for interference; a sample dilution of 1:100 or greater is often required because the extract contains beta-glucans that may activate LAL reagents. Sterility is assessed per USP <71>, and particulate matter per USP <788> is applied according to the container fill volume. The terminal product is a sterile injectable solution packaged in amber borosilicate vials or ampoules for intramuscular or subcutaneous administration in cattle and swine.

Before fluid-bed granulation of the drinking-water powder, the extract is blended with a soluble carrier system and a binder solution to form free-flowing granules that disperse quickly in nipple-drinker lines. The carrier consists of lactose monohydrate, maltodextrin DE 15–20, and anhydrous citric acid to control local pH. A binder solution of povidone K30 at 5% w/w in purified water is sprayed onto the fluid-bed charge. The finished granule is controlled so that no more than 10% w/w is retained on a 800 µm sieve and no more than 10% w/w passes through a 100 µm sieve. Sieve analysis is performed using ISO 3310-1 test sieves. Fine-particle content below 75 µm is limited because it can settle in long pipe runs and clog pressure regulators in commercial poultry houses operating at 1.5–2.5 bar line pressure.

Granulation is performed in a top-spray fluid-bed dryer with inlet air at 60–65°C and product temperature at 38–42°C. Spray rate is adjusted so that granule moisture remains between 8% and 12% w/w during the wet phase; terminal drying continues to not more than 2.0% loss on drying at 85°C. The dried material is passed through an oscillating granulator fitted with a 0.8 mm screen to break overs. Dispersibility is evaluated in a 1 L beaker with 20°C hard water at 500 mg/L CaCO₃ equivalent; complete dispersion without stirring should occur in 60 sec. The finished powder is packaged in aluminum foil-lined sacks with desiccant because the botanical fraction is hygroscopic.

The powder should not be administered simultaneously with chlorine dioxide, ozone, or strong oxidizing drink-line sanitizers. Oxidative attack on berberine-type alkaloids and flavonoid phenolic groups causes color shift and may reduce marker recovery. If continuous chlorination is used, the dosing pump is disconnected and the line is flushed with citric acid solution at 1 g/L before and after the medication period. For field dilution, the powder is prepared as a concentrated stock solution of 50–100 g/L and then dosed into the drinking water at a rate determined by the registered finished product label. Microbial quality is tested according to USP <61> and USP <62>. The terminal product is a water-soluble oral powder or granule for poultry and swine drinking-water administration.

Feed-Premix Carrier Selection and Segregation Control

Feed-premix carrier selection is governed by flowability, dust control, and inertness toward the extract's polyphenolic fraction. Calcium carbonate, rice hull meal, wheat bran, soybean mill feed, and sodium aluminosilicate are used after drying to ≤12% w/w moisture and milling through a 0.5 mm screen. A two-stage dilution is preferred. The extract is first mixed with a 1:9 ratio of calcium carbonate in a ribbon blender; after 10 min this intermediate premix is further diluted at 1:10 with the main carrier. Vegetable oil is sprayed into the mixer at 1%–2% w/w to reduce dust and bind fine extract particles to the carrier. Homogeneity is assessed by sampling 10 points across the batch and assaying a marker compound; the coefficient of variation should be ≤8% after 15 min of mixing. If CV exceeds 10%, a pre-mill and a second blending step are introduced.

The concentrated premix should be stored in sealed sacks at ≤25°C and ≤60% RH. Carriers such as rice hull meal and wheat bran with moisture above 12% provide conditions for mold growth and extract clumping. Direct contact with propionic acid or other acid preservatives must be avoided in the production sequence because the extract becomes wet and sticky. If the premix is incorporated into mash feed before pelleting, conditioning at 75–85°C for 20–30 sec can reduce heat-sensitive marker content by 5%–12%. The extract premix is therefore added post-pelleting through a liquid or dust coating drum, or an overage is established in the registered formulation. Published pelleting stability data for this specific extract combination are limited, so a pilot-scale pellet mill run with die temperature monitoring is performed before commercial scale-up. Premix manufacture should follow Regulation (EC) 183/2005 Annex II, and sampling may be performed according to ISO 6497:2005. The terminal product is a medicated feed premix for pigs, poultry, or other food-producing species after local registration is confirmed.

When the Extract Premix Moves into Capsule Filling for Companion Animals

When the extract premix moves into capsule filling for companion animals, the granulate must meet narrow flow-density windows because dosator and auger machines respond strongly to bulk density changes. Direct filling of unmilled extract can produce erratic fill weights because the powder is cohesive and hygroscopic. A roller compaction or slugging step is introduced when the bulk density falls below 0.45 g/mL or the Carr index exceeds 25%. The granulated intermediate is filled into hard gelatin capsules or HPMC capsules using an intermittent-motion dosator machine with tamping pins adjusted to produce fill weights of 100 mg to 500 mg per capsule depending on the target dose. At speeds around 60,000 capsules per hour, the fill weight variation should be controlled to ±5%; a running tolerance of ±3% is typical when the granulate tapped density is 0.50–0.65 g/mL and the angle of repose is below 35°.

The encapsulation suite is maintained at 40–45% RH and 18–22°C. Gelatin shells become brittle below 40% RH and loose above 65% RH; HPMC capsules provide a wider tolerance but are still specified at ≤50% RH for this fill. The filled capsules are packaged in cold-form aluminum foil blisters if the extract contains light-sensitive or volatile components. Dissolution is tested per USP <711> with 0.1 N HCl as the initial medium. If the powder forms a gelatinous plug in the basket or the capsule shell does not rupture, crospovidone or crosslinked sodium carboxymethyl starch is added at 2%–4% w/w to the granulate. The extract premix should not be filled directly into soft gelatin capsules because the hygroscopic powder may migrate into the shell and crosslink gelatin; if soft gels are unavoidable, the fill vehicle must be fully hydrophobic and the extract should be passed through a 0.15 mm screen before dispersion. The terminal product is an oral hard capsule for dogs, cats, or calves.

Terminal Heat Exposure Sets a Process Boundary for Oral Solutions

Terminal heat exposure sets a process boundary for oral solutions and drenches. The extract is dispersed in a buffered aqueous vehicle rather than subjected to extended thermal processing. A common vehicle contains purified water, glycerin at 5%–15% w/w, and propylene glycol at 5%–15% w/w as co-solvents. The extract is added at 2%–5% w/w total solids under continuous low-shear agitation. Mixing temperatures above 50°C are avoided because polyphenol oxidation increases with temperature and the solution darkens. The preservative system consists of sodium benzoate at 0.1%–0.2% w/w and potassium sorbate at 0.1%–0.2% w/w. Preservative efficacy is maintained only when pH is below 5.5; above this, benzoate activity decreases. If the pH is raised above 6.0, the formulation is challenged by USP <51> antimicrobial effectiveness testing rather than relying on preservative concentration alone.

When a suspension is needed to improve physical stability, the coarse dispersed extract is passed through a high-shear rotor-stator homogenizer at 4,000–8,000 rpm for 10–15 min, with the vessel jacket cooled to ≤8°C. Particle size is checked by laser diffraction; D90 below 20 µm is required for a pourable drench, and below 10 µm if the product is intended for oral syringes. Xanthan gum at 0.2%–0.3% w/w or microcrystalline cellulose/carboxymethylcellulose sodium at 0.5%–1.5% w/w is added to reduce sedimentation after 24 h at 25°C. The finished oral liquid is not terminally sterilized; it is produced under hygienic conditions and tested for microbial enumeration per USP <61> and for absence of Escherichia coli, Salmonella, Staphylococcus aureus, and Pseudomonas aeruginosa per USP <62>. Amber polyethylene terephthalate or glass bottles are used to limit light transmission below 380 nm, and headspace oxygen is reduced by nitrogen flushing to ≤2% v/v.

The aqueous vehicle must not contain ferric salts or heavy-metal contaminants because phenolic acids in the extract can form dark iron-polyphenol complexes. Product-contact surfaces in the filling line are specified as 316L stainless steel rather than mild steel. Contact with strong oxidizing or reducing agents is avoided during line cleaning to prevent formation of colored breakdown products. Published data for long-term stability in this specific extract-vehicle system are limited; real-time stability storage at 25°C/60% RH and 40°C/75% RH is used to set the shelf life. The terminal product is an oral solution or drench for calves, piglets, foals, or companion animals.